Peanut allergy and oral immunotherapy.

Area of Science:

• Allergy and Immunology
• Clinical Therapeutics
• Food Hypersensitivity

Background:

• Peanut allergy is a leading cause of fatal food-induced anaphylaxis globally.
• Current research focuses on developing safe and effective desensitization methods.
• Combination therapy offers a promising avenue for managing peanut allergy.

Purpose of the Study:

• To evaluate the efficacy and safety of combined anti-immunoglobulin E and oral immunotherapy for peanut desensitization.
• To assess the increase in tolerated peanut protein dose.
• To determine the incidence and severity of adverse reactions during treatment.

Main Methods:

• Treatment of 27 patients with a combination of anti-immunoglobulin E and oral immunotherapy.
• Monitoring of peanut protein tolerance levels before and after desensitization.
• Systematic recording of adverse reactions during oral immunotherapy escalation and maintenance phases.

Main Results:

• Median tolerated peanut protein dose increased from 5 mg to 2000 mg post-desensitization.
• Low incidence of adverse reactions: 1.8% during escalation and 0.6% during maintenance.
• Most adverse reactions were mild; only three required treatment withdrawal, none needed epinephrine.

Conclusions:

• Combined anti-immunoglobulin E and oral immunotherapy is an effective and safe approach for peanut desensitization.
• The treatment significantly enhances peanut tolerance, exceeding levels likely from accidental ingestion.
• Preliminary findings suggest sustained tolerance requires continued daily peanut ingestion.